“…Additionally, mixed chimerism or late secondary graft failure remain obstacles to longer-term successful outcomes in BMT for SAA. 3 Survival rates following MSD allogeneic BMT have steadily improved since the 1970s largely because of improved supportive care, refined HLA-typing, and better GVHD prophylaxis. 2 However, late BMT-related complications such as chronic GVHD occur in up to one-third of patients, with many of these patients requiring long-term therapy for their GVHD.…”